乳腺癌肿瘤抑制候选基因5基因启动子甲基化水平研究
PDF下载 (414)楼婷婷1,柯孔亮2,张乐鸣2*.乳腺癌肿瘤抑制候选基因5基因启动子甲基化水平研究[J].宁波大学学报(理工版),2015,28(03):108-112.DOI:
LOU Ting-ting1,KE Kong-liang2,ZHANG Le-ming2*.Study: Promoter Methylatin Status of Tusct Gene in Breast Cancer[J].Journal of Ningbo University(Natural Science & Engineering Edition),2015,28(03):108-112.DOI:
| Title: | Study: Promoter Methylatin Status of Tusct Gene in Breast Cancer |
| 作者: | 楼婷婷1, 柯孔亮2, 张乐鸣2* |
| Author(s): | LOU Ting-ting1, KE Kong-liang2, ZHANG Le-ming2* |
| 关键词: | 乳腺癌; TUSC5基因; 甲基化; 焦磷酸测序; 细胞株 |
| Keywords: | qRT-PCR; breast cancer; TUSC5 gene; methylation; pyrosequencing; cell lines |
| 分类号: | R730.2; R737.9 |
| 文献标识码: | A |
| 摘要: | 探讨人正常乳腺细胞株及不同乳腺癌细胞株肿瘤抑制候选基因5启动子甲基化状态, 并分析其与雌激素受体、孕激素受体、人类表皮生长因子受体2的表达相关性. 运用焦磷酸测序分析4种乳腺癌细胞株和1种人类正常乳腺细胞株中TUSC5基因启动子甲基化状态, 以及实时荧光定量逆转录聚合酶反应和Western印迹来检测这些细胞株中TUSC5基因mRNA和蛋白的表达. 结果表明: 正常人类乳腺细胞株存在TUSC5基因启动子低甲基化, 而4种乳腺癌细胞株存在不同程度高甲基化; 在4种乳腺癌细胞株中, 激素受体及HER-2表达阴性即三阴性乳腺癌细胞TUSC5基因启动子甲基化水平较非三阴性乳腺癌细胞低; 并且乳腺癌的发生可能与TUSC5基因启动子高甲基化有关, 乳腺癌TUSC5基因启动子甲基化水平与激素受体、HER-2表达具有一定相关性, 其发生的机制需进一步研究探讨. |
| Abstract: | To investigate the promoter methylation status of TUSC5 gene in human breast cell and human breast cancer cell lines, and the relationship between hormone receptor and HER-2 status of TUSC5 expression. Pyrosequencing is used to measure the promoter methylation status of TUSC5 gene in four human breast cancer cell lines and one human breast cell. qRT-PCR and Western blot are used to detect the mRNA and protein expressions of TUSC5 gene. It is found that the human breast cell line(MCF-10A) shows low-methylated status and 4 human breast cancer cell lines show high-methylated status. However, the high-methylated status of the breast cancer line with the negative expressions of ER /PR and HER-2(TNBC, triple-negative breast cancer) is lower than the non-triple-negative breast cancer cell lines. Pathogenesis of breast cancer may be connected with the promoter methylation status of TUSC5 gene in human breast cancer, and its high-methylated status is related to the expression of hormone receptor and HER-2, but the mechanism is currently unknown and needs being further studied |
| 参考文献 /References: | [1]. 2011年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2015, 24(1):1-10. [2].Portela A, Esteller M. Epigenetic modifications and human disease [J]. Nat Biotechnol, 2010, 28(10):1057- 1068. [3].Pang K L, Sukumar S. Epigenomics and breast cancer[J]. Pharmacogenmics, 2008, 9(12):1879-1902. [4].Connolly R, Stearns V. Epigenetics as a Therapeutic Target in Breast Cancer[J]. Mammary Gland Biol Neoplasia, 2012, 17(3/4):191-204. [5].Konishi H, Sugiyama M, Mizuono K, et al. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at distal 17p13.3 in human lung cancer[J]. Oncogene, 2003, 22:1892-1905. [6].Aoki M, Seqawa H, Naito M, et al. Identification of possible downstream genes required for the extension of peripheral axons in primary sensory neurons[J]. Biochem Biophys Commun, 2014, 445(2):357-362. [7].Bubnov V, Moskalev E, Petrovskiy Y, et al. Hypermethylation of TUSC5 genes in breast cancer tissue[J]. Exp Oncol, 2012, 34(4):370-372. [8].Knotts T A, Lee H W, Kim J B, et al. Molecular characterization of the tumor suppressor candidate 5 gene: Regulation by PPARγ and identification of TUSC5 coding variants in lean and obese humans[J]. PPAR Res, 2009, 2009:867678-867685. [9].Ouadidi A H, Rodat D L, Matifat F et al. DNA methylation of channel-related genes in cancers[J]. Biochim Biophys Acta, 2015, 2736(15):55-57. [10].Filetici P. Epigenetics: a novel tool for early diagnosis and tumor therapy[J]. Recenti Prog Med, 2015, 106(1): 32-34. [11].Oort P J, Warden C H, Baumann T K, et al. Chara- cterization of Tusc5, an adipocyte gene co-expressed in peripheral neurons[J]. Mol Cell Endocrinol, 2007, 276(1/2):24-35. [12].Raquel S A, Luiz O P, Edward M M, et al. Global signatures of protein and mRNA expression levels[J]. Mol Biosyst, 2009(5):1512-1526. [13].Lacroix M, Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: An update[J]. Breast Cancer Res Treat, 2004, 83(3):249-289. |
| 备注/Memo: | 收稿日期: 2015?03?11. 宁波大学学报（理工版）网址: http://journallg.nbu.edu.cn/ 第一作者: 楼婷婷（1984－）, 女, 浙江丽水人, 在读硕士研究生, 主要研究方向: 乳腺肿瘤疾病. E-mail: 77563078@qq.com *通信作者: 张乐鸣（1956－）, 男, 浙江宁波人, 主任医师, 主要研究方向: 肿瘤疾病. E-mail: kekongliang1975@163.com 宁波大学学报（理工版）网址：http://journallg.nbu.edu.cn/ |
